A new focused update of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) dyslipidaemia guidelines, announced at the ESC 2025 congress, recommends that an elevated Lp(a) >50 mg/dL (>105 nmol/L) should be considered as a cardiovascular (CV) risk-enhancing factor in all adults, with higher Lp(a) levels associated with a greater increase in risk (Class IIa recommendation, level B evidence).
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.